🇺🇸 FDA
Patent

US 10226472

Methods for the treatment of breast cancer

granted A61KA61K31/4196A61K31/4406

Quick answer

US patent 10226472 (Methods for the treatment of breast cancer) held by Syndax Pharmaceuticals, Inc. expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Syndax Pharmaceuticals, Inc.
Grant date
Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/4196, A61K31/4406, A61K31/566, A61K31/5685